Shy Therapeutics LLC

Cyber Switching, Inc.

Janssen Pharmaceutica Nv

Cyberswitchingpatents, LLC

Other

Rohm and Haas Company

Madrigal Pharmaceuticals, Inc.

Nura Bio, Inc.

Cyber Switching Solutions, Inc.

Hoffmann-La Roche Inc.

F. Hoffmann-La Roche Ag

Charles Howard Reynolds

Theresa M Williams

Yaron R Hadari

Michael Schmertzler

Luca Carta

Rebecca Hutcheson

Ronald L Silorio

Allen B Reitz

Ellen W Baxter

Tina Morgan Ross

Yifang Huang

Christopher John Creighton

Chi Luo

Tianbao Lu

Steven H Shaber

Brett A Tounge

Ron L Silorio

Christopher Michael Tegley

Cheryl A Grice

Andrew Stewart Tasker

David Newcomb

Liusheng Zhu

Robert E Boyd

Chih Yung Ho

Rao Kolluri

Michael H Parker

Mark J Schulz

Eric D Strobel

Edward Michael Szapacs

Rebecca Taub

Alfonzo D Jordan

Sean Pomeroy Brown

Glen William Osterhout

Ping Wang

Serge Maria Aloysius Pieters

Steven J Coats

Marc Mercken

Martha Jean Kelly

Gregory A Reynolds

Ellen Sieber-McMaster

Hans Louis Jos De Winter

François Paul Bischoff

Eric Jon Langenmayr

Robert J Duguid

Steve Coats

Lianhe Shu

Mirielle Braeken

Nikoi Annan

Duk Soon Choi

Malcolm Scott

D Keith Hester, Ii

Anna Chasnoff

Gang Dong

Edwin L Crow

Anna Sabath

Sufang Zhang

Carolina Bigarella

Ellen E Baxter

Hans De Winter

Umar Saibu Mohomed Maharoof

Keith D Hester

D Keith Hester

Provided herein are compounds of Formula I, or a pharmaceutically acceptable form thereof, and pharmaceutical compositions comprising the same. Also provided herein methods of modulating the activity of cellular targets by administering to a subject a compound of Formula I, or a pharmaceutically acceptable form thereof. Further provided herein are methods of treating cancer, fibrotic diseases, and inflammatory diseases by administering to a subject a compound of or a pharmaceutically acceptable form thereof.

Compounds that interact with RAS superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a method for assaying such compositions.

Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

An electric vehicle (EV) charging system includes a number of output connections (e.g., cables). Each of the output connections is connected to at least one head, and each head can be connected concurrently to an EV. A controller can direct a charging current, delivered over a dedicated circuit from an electric power supply, to a first one of the output connections if a first EV is connected to a head connected to the first one of the output connections. Then, the charging current to the first one of the output connections can be stopped, switched to a second one of the output connections, and restarted if a second EV is connected to a head connected to the second one of the output connections.

Electric vehicle charging system

Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.

Compounds for the treatment of cancer and inflammatory disease

This disclosure is drawn to pyridine derivatives, compositions thereof, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological disorders.

Substituted pyridine derivatives as SARM1 inhibitors

A method of charging one or more electric vehicles (EVs) includes receiving a voltage over a dedicated circuit from an electric power supply. A charging current is generated using the voltage and directed to a first output connection if a first EV is connected to a head that is connected to the first output connection. The charging current to the first one of the output connections is stopped, then directed to a second output connection if a second EV is connected to a head coupled to the second output connection.

Electric vehicle charging method

An electric vehicle (EV) charging system includes a number of output connections (e.g., cables). Each of the output connections is connected to at least one head, and each head can be connected concurrently to an EV. A charging current is directed to a first one of the output connections if a first EV is connected to a head connected to the first one of the output connections. Then, the charging current to the first one of the output connections can be stopped, switched to a second one of the output connections, and restarted if a second EV is connected to a head connected to the second one of the output connections. A graphical user interface (GUI) is rendered on the display of a computer system. The GUI includes elements that indicate which output connection of the charging station is receiving a charging current.

Electric vehicle charging system interface

Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.

Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease

A first controller can be coupled to a main power supply and deliver a first charging current to an electric vehicle (EV) at a first charging station. The first controller can also deliver power to a second controller that can provide a second charging current to an EV at a second charging station. The first controller turns off the power to the second controller in response to determining that there is an EV charging at the first charging station, and turns on the power to the second controller only in response to determining that an EV is not charging at the first charging station.

Electric vehicle charging system with priority charging

Growing community of inventors

Austin, TX, United States of America

Charles Howard Reynolds